PCM
AKBA icon

Pinz Capital Management’s Akebia Therapeutics AKBA Stock Holding History

Pinz Capital Management’s Portfolio AKBA Stock Details AKBA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-6,300
Closed -$24K – 148
2021
Q2 		$24K Buy
+6,300
New +$21.2K 0.01% 312

Other funds holding AKBA

State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
NCM
Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return
AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return

Pinz Capital Management's AKBA Position: Q3 2021 in Review

Pinz Capital Management sold out of Akebia Therapeutics (AKBA) in Q3 2021, closing a stake of 6,300 shares — an estimated $24K sold.

Pinz Capital Management first reported a position in AKBA in Q2 2021 and held it in 1 quarter. The position peaked at $24K in Q2 2021. 126 funds tracked by Wall St. Rank hold AKBA as of Q3 2021.

  • Pinz Capital Management reported no remaining Akebia Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Pinz Capital Management sold 6,300 Akebia Therapeutics shares in Q3 2021, an estimated $24K.
  • Pinz Capital Management first reported a position in Akebia Therapeutics in Q2 2021 and held it in 1 quarter.
  • Pinz Capital Management's Akebia Therapeutics position peaked at $24K in Q2 2021.
  • 126 funds tracked by Wall St. Rank held Akebia Therapeutics as of Q3 2021.

Based on Pinz Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.